Latigo Bio is a clinical-stage biopharmaceutical company based in Thousand Oaks, California. The firm focuses on developing non-opioid pain medicines, an area of significant medical need given the ongoing challenges associated with opioid-based therapies. Its approach integrates human genetics, biology, and advanced drug design methodologies, including structure-based and computer-assisted techniques.
The company's pipeline includes two selective Nav1.8 ion channel inhibitors, LTG-001 and LTG-305, both in clinical development for pain relief. Nav1.8 is a sodium channel that plays a key role in pain signal transmission, making it an attractive target for non-opioid analgesics. Multiple pain programs have advanced into clinical development, supported by top-tier investors.
